105 related articles for article (PubMed ID: 6616494)
21. Active-controlled, non-inferiority trials in oncology: arbitrary limits, infeasible sample sizes and uninformative data analysis. is there another way?
Carroll KJ
Pharm Stat; 2006; 5(4):283-93. PubMed ID: 17128427
[TBL] [Abstract][Full Text] [Related]
22. Adaptive signature design: an adaptive clinical trial design for generating and prospectively testing a gene expression signature for sensitive patients.
Freidlin B; Simon R
Clin Cancer Res; 2005 Nov; 11(21):7872-8. PubMed ID: 16278411
[TBL] [Abstract][Full Text] [Related]
23. [Current status and issues in clinical trials of anticancer agents].
Kojima H
Gan To Kagaku Ryoho; 1994 Oct; 21 Suppl 3():295-301. PubMed ID: 7986107
[TBL] [Abstract][Full Text] [Related]
24. Stopping clinical trials early for benefit: impact on estimation.
Freidlin B; Korn EL
Clin Trials; 2009 Apr; 6(2):119-25. PubMed ID: 19342463
[TBL] [Abstract][Full Text] [Related]
25. Phase 0 clinical trials in oncology: a paradigm shift for early drug development?
Takimoto CH
Cancer Chemother Pharmacol; 2009 Mar; 63(4):703-9. PubMed ID: 18615251
[TBL] [Abstract][Full Text] [Related]
26. Novel designs and end points for phase II clinical trials.
Adjei AA; Christian M; Ivy P
Clin Cancer Res; 2009 Mar; 15(6):1866-72. PubMed ID: 19276272
[TBL] [Abstract][Full Text] [Related]
27. Continuous toxicity monitoring in phase II trials in oncology.
Ivanova A; Qaqish BF; Schell MJ
Biometrics; 2005 Jun; 61(2):540-5. PubMed ID: 16011702
[TBL] [Abstract][Full Text] [Related]
28. Assessment of toxicity in cooperative oncology clinical trials: the long and short of it.
Gwede CK; Johnson DJ; Daniels SS; Trotti A
J Oncol Manag; 2002; 11(2):15-21. PubMed ID: 11989815
[TBL] [Abstract][Full Text] [Related]
29. Practical considerations in planning and conducting clinical trials with investigational or marketed drugs.
Spilker B
Clin Neuropharmacol; 1983; 6(4):325-47. PubMed ID: 6661731
[TBL] [Abstract][Full Text] [Related]
30. Interim analyses for randomized clinical trials: the group sequential approach.
Pocock SJ
Biometrics; 1982 Mar; 38(1):153-62. PubMed ID: 7082757
[TBL] [Abstract][Full Text] [Related]
31. Clinical trial design in metastatic breast cancer: a commentary.
Levine M
Can J Oncol; 1995 Dec; 5 Suppl 1():40-2. PubMed ID: 8853523
[TBL] [Abstract][Full Text] [Related]
32. Methodological and design issues in clinical trials of new neuroleptics: an overview.
Awad AG
Br J Psychiatry Suppl; 1993 Dec; (22):51-7. PubMed ID: 7906524
[TBL] [Abstract][Full Text] [Related]
33. Phase II clinical trials in oncology: strengths and limitations of two-stage designs.
Schlesselman JJ; Reis IM
Cancer Invest; 2006; 24(4):404-12. PubMed ID: 16777694
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of toxicity: statistical considerations.
Herson J
Cancer Treat Rep; 1980; 64(2-3):463-8. PubMed ID: 7407785
[TBL] [Abstract][Full Text] [Related]
35. Immunological monitoring of clinical trials using biological response modifiers.
Maluish AE
Lymphokine Res; 1986; 5 Suppl 1():S183-7. PubMed ID: 3784612
[TBL] [Abstract][Full Text] [Related]
36. [The need for a multicenter approach in establishing a phase III clinical trial in oncology].
Dalesio O; Hart AA
Ned Tijdschr Geneeskd; 1988 Jul; 132(29):1321-2. PubMed ID: 3412498
[No Abstract] [Full Text] [Related]
37. Analysis of duration of response in oncology trials.
Ellis S; Carroll KJ; Pemberton K
Contemp Clin Trials; 2008 Jul; 29(4):456-65. PubMed ID: 18187370
[TBL] [Abstract][Full Text] [Related]
38. [Data input management in clinical trial].
Nakajima T
Gan To Kagaku Ryoho; 1991 Jul; 18(9):1409-14. PubMed ID: 1854211
[TBL] [Abstract][Full Text] [Related]
39. A phase II clinical trial of cytembena. Clinical screening group of E.O.R.T.C.
Biomedicine; 1977 Dec; 26(6):392-5. PubMed ID: 342004
[TBL] [Abstract][Full Text] [Related]
40. Minimal guidelines for the monitoring of early clinical trials (phase I-II) in Europe under CRC/EORTC/NCI joint agreement.
Arrigo C; Koier IJ; McVie JG; Marsoni S; Newlands E; Schwartsmann G
Eur J Cancer; 1992; 28A(6-7):1289-92. PubMed ID: 1627396
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
